TY  - JOUR
T1  - NEw and nonofficial drugs
Y1  - 1959/07/11
N1  - 10.1001/jama.1959.63010110010012a
JO  - Journal of the American Medical Association
SP  - 1316
EP  - 1317
VL  - 170
IS  - 11
N2  - Valethamate Bromide (Murel).— 
    2-Diethylaminoethyl 3-methyl-2-phenylvalerate methylbromide.— The structural formula of valethamate bromide may be represented as follows:Actions and Uses.— 
    Valethamate bromide, introduced in 1958, is a quaternary ammonium compound which is used clinically as an antispasmodic. Animal experiments indicate that the drug acts predominantly as an anticholinergic agent. In addition, it exerts a mild direct inhibiting effect on the motility of smooth muscle. Valethamate is also said to exhibit a transient ganglionic blocking action; such effects are minimal, if not imperceptible, in the doses used clinically. The drug does not diminish gastric secretion to any appreciable extent.Valethamate bromide is proposed for oral and parenteral use for the treatment of hypermotility and spasm of the gastrointestinal, genitourinary, and biliary tracts as well as for the adjunctive management of peptic ulcer. Although favorable results have been reported in some patients, the bulk of the clinical evidence available to date is
SN  - 0002-9955
M3  - doi: 10.1001/jama.1959.63010110010012a
UR  - http://dx.doi.org/10.1001/jama.1959.63010110010012a
ER  -